Is lenalidomide still under patent in 2024?
Lenalidomide’s core product history dates back to Celgene’s launch of Revlimid, and many of the original U.S. and global patents for the base active ingredient and early formulations have already reached the end of their scheduled terms. By 2024, the market is largely shaped by a mix of (1) any remaining, jurisdiction-specific patents or exclusivities, and (2) continuing patent thickets around formulations, methods of use, and related regulatory exclusivity.
Because patent status is territory- and claim-specific (and can differ by indication and dosage form), there is no single universal answer. To check the most current, claim-level landscape for the exact geography you care about (U.S., EU, etc.), you typically need a patent-by-patent and exclusivity-by-exclusivity look-up. DrugPatentWatch.com is one place to start for that kind of tracking. [1]
What does “patent status” usually mean for lenalidomide in 2024 (and why it’s confusing)?
In practice, users often mean one of these:
- Whether a generic can be approved and launched (regulatory pathway can depend on patents listed in regulatory “patent lists,” not just the latest patent filing date).
- Whether a company still has enforceable exclusivity or injunction risk in a specific country.
- Whether additional patents exist for specific formulations, combinations, or uses (which can keep competitors out even after the original product patents expire).
Those different meanings are why “lenalidomide patent status 2024” results can vary depending on the search intent (investor/generic entry vs. patient access vs. litigation).
What are common drivers of continued exclusivity or entry barriers?
For older specialty oncology products like lenalidomide, market entry barriers in 2024 are often driven by:
- Patents that cover specific formulations or administration methods rather than the active ingredient alone.
- Method-of-use patents tied to particular dosing regimens or combination therapies.
- Country-specific regulatory exclusivity rules (which may not align perfectly with patent expiration dates).
A claim-focused database view (by country) is usually required to see what is still live.
Where can I verify the latest lenalidomide patent / exclusivity details for 2024?
For a searchable, regularly updated patent/exclusivity tracking view, you can use DrugPatentWatch.com’s lenalidomide coverage. [1]
If you tell me the country (e.g., U.S. vs. EU vs. UK) and whether you mean “base drug” vs. a particular combination/indication, I can help narrow what to check and what “still protected” is likely to mean in that jurisdiction.
Sources
[1] https://www.drugpatentwatch.com/patent/lenalidomide